Home
About Us
Overview
Business Model
Milestones
Our Presence
Board of Directors
Mission, Vision and Values
Environment
Products
Research & Development
Product Development
R & D Capabilities
Infrastructure
Capacities and Capabilities
Regulatory Approvals
Investor Relations
Overview
Financial Highlights
Annual Report
Code of Conduct
Shareholding Pattern
Recent News
Contact Us
Sales Offices
Enquiry Form
FAQs
Investor Relations
Overview
Financial Highlights
Annual Report
Code of Conduct
Shareholding Pattern
Recent News
Contact
Granules Investor Enquiry
E-mail:
vijay.ramanavarapu@granulesindia.com
investorrelations@granulesindia.com
Investor Relations
Financials (Consolidated)
Grew revenue to Rs. 289.3 cr in nine months in FY08-09 from Rs. 256.5 cr in FY07-08, an increase of 12.8% (50.4% on an annualised basis)
EBIDTA grew to Rs. 42.9 cr in FY08-09 from Rs. 36.5 cr in FY07-08, an increase of 17.8% (57.1% on an annualised basis)
Dividend of Rs. 1.25 per share (Rs. 10 face value)
View all
Stock Quote
Stock Exchange: BSE
Quotes delayed by at least 15 minutes
For NSE stock updates click
here
Recent News
Granules India Posts Revenue of Rs.109.3 Cr. for Q1 FY11
Granules India Posts Strong Growth During FY’10: Net Revenue of Rs. 461.1 Cr.
Granules India Receives U.S. FDA Approval for its Metformin ANDA
Granules India Posts Record Revenue for a Quarter: Net Revenue of Rs. 122.40 Cr. Posted for Q3 FY’10
Granules Posts Record Revenue, Net Profit Increases 121%
View all
Stock Chart